---
figid: PMC8637646__gr2
figtitle: 'Metabolic therapy and bioenergetic analysis: The missing piece of the puzzle'
organisms:
- Homo sapiens
- Mus musculus
- Saccharomyces cerevisiae
- unidentified
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8637646
filename: gr2.jpg
figlink: /pmc/articles/PMC8637646/figure/fig2/
number: F2
caption: 'Tumoral bioenergetic metabolism at a glance. Glucose enters transformed
  cells via GLUT family transporters and undergoes glycolysis, converted into pyruvate
  (yielding 2 net ATP). Cancer cells preferentially divert pyruvate to lactate (SLP),
  regardless of the presence of oxygen (aerobic glycolysis or Warburg effect); an
  estimated 10% of pyruvate goes toward biosynthesis, and OXPHOS is variable, depending
  on mitochondrial dysfunction. Oxygen consuming, mitochondrially defective cancer
  cells can utilize glucose-derived pyruvate, glutamine, and fatty acids to drive
  TCA cycle intermediaries, but ATP-generation capacity through the ETC is impaired
  to a substantial degree. In conditions of glucose and glutamine deprivation, recycling
  of ancillary substrates could aid in ATP generation, including fatty acids/ketone
  bodies, lactate, amino acids and autophagic processes. Metabolic reprogramming involves
  the interconnected regulation of glycolysis, glutaminolysis and mitochondrial metabolism.
  Prominent regulators are P53 (glycolysis/OXPHOS), CMYC (glycolysis, glutaminolysis
  and lipid synthesis), KRAS (glycolysis, glutaminolysis), PI3K/AKT (glycolysis),
  AMPK (nutrient stress), HIF-1 (glycolysis, global metabolic rewiring), peroxisome
  proliferator-activated receptors (PPARs) and PPARγ coactivator-1α (PGC-1α) (FAO),
  forkead box O family (FOXO) (OXPHOS). The combination of preexisting oncogenic lesions
  and metabolic fluxes, along with tumoral milieu, is likely to govern metabolic flexibility
  of each individual cell. Abbreviations: PPP (Pentose phosphate pathway), SLP (substrate
  level phosphorylation), OXPHOS (oxidative phosphorylation), ROS (reactive oxygen
  species).'
papertitle: 'Metabolic therapy and bioenergetic analysis: The missing piece of the
  puzzle.'
reftext: Tomás Duraj, et al. Mol Metab. 2021 Dec;54:101389.
year: '2021'
doi: 10.1016/j.molmet.2021.101389
journal_title: Molecular Metabolism
journal_nlm_ta: Mol Metab
publisher_name: Elsevier
keywords: Cancer | Energy metabolism | Glycolysis | Oxidative phosphorylation | Research
  design
automl_pathway: 0.8982159
figid_alias: PMC8637646__F2
figtype: Figure
redirect_from: /figures/PMC8637646__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8637646__gr2.html
  '@type': Dataset
  description: 'Tumoral bioenergetic metabolism at a glance. Glucose enters transformed
    cells via GLUT family transporters and undergoes glycolysis, converted into pyruvate
    (yielding 2 net ATP). Cancer cells preferentially divert pyruvate to lactate (SLP),
    regardless of the presence of oxygen (aerobic glycolysis or Warburg effect); an
    estimated 10% of pyruvate goes toward biosynthesis, and OXPHOS is variable, depending
    on mitochondrial dysfunction. Oxygen consuming, mitochondrially defective cancer
    cells can utilize glucose-derived pyruvate, glutamine, and fatty acids to drive
    TCA cycle intermediaries, but ATP-generation capacity through the ETC is impaired
    to a substantial degree. In conditions of glucose and glutamine deprivation, recycling
    of ancillary substrates could aid in ATP generation, including fatty acids/ketone
    bodies, lactate, amino acids and autophagic processes. Metabolic reprogramming
    involves the interconnected regulation of glycolysis, glutaminolysis and mitochondrial
    metabolism. Prominent regulators are P53 (glycolysis/OXPHOS), CMYC (glycolysis,
    glutaminolysis and lipid synthesis), KRAS (glycolysis, glutaminolysis), PI3K/AKT
    (glycolysis), AMPK (nutrient stress), HIF-1 (glycolysis, global metabolic rewiring),
    peroxisome proliferator-activated receptors (PPARs) and PPARγ coactivator-1α (PGC-1α)
    (FAO), forkead box O family (FOXO) (OXPHOS). The combination of preexisting oncogenic
    lesions and metabolic fluxes, along with tumoral milieu, is likely to govern metabolic
    flexibility of each individual cell. Abbreviations: PPP (Pentose phosphate pathway),
    SLP (substrate level phosphorylation), OXPHOS (oxidative phosphorylation), ROS
    (reactive oxygen species).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - mct1
  - Slc16a1
  - Mcts1
  - Slc1a3
  - C4a
  - Skiv2l-ps1
  - Slc16a3
  - Gnat2
  - Tas2r145-ps3
  - Mtor
  - Tigar
  - Rr149356
  - Pten
  - Ar
  - ras
  - Hras
  - Kras
  - Rem1
  - Myc
  - Nol3
  - Creb1
  - Afg3l2
  - Fth1
  - Decr1
  - Fancd2
  - pk
  - Idh1
  - Mapk8
  - Nrf1
  - Nfe2l1
  - Ppargc1a
  - Idh2
  - Rfpw2
  - .na.character
  - Slc38a1
  - Slc7a5
  - CMA1
  - SLC16A1
  - MCAT
  - MCTS1
  - SLC2A1
  - SLC16A4
  - SLC16A3
  - TAS2R6P
  - MTOR
  - TIGAR
  - PTEN
  - AR
  - KRAS
  - HRAS
  - NRAS
  - MYC
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - NR1I2
  - JTB
  - DECR1
  - ATP8A2
  - BRCA2
  - FANCD2
  - PSEN1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - IDH1
  - HIF1A
  - SETD2
  - ARNT
  - E2F1
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - E2F8
  - MAPK8
  - MAPK9
  - MAPK10
  - NOTCH1
  - NOTCH2
  - NOTCH3
  - NOTCH4
  - NRF1
  - NFE2L1
  - PPARGC1A
  - TAM
  - STIM1
  - IDH2
  - DAPK1
  - DAPK2
  - DAPK3
  - STK17A
  - STK17B
  - SLC38A1
  - SLC7A5
  - Mct1
  - Eaat1
  - Glut1
  - Glut4EF
  - Glut3
  - slp1
  - slp2
  - CycE
  - cyc
  - scb
  - Tor
  - aop
  - eb
  - ar
  - bsk
  - Ras64B
  - Ras85D
  - sgg
  - foxo
  - SNF4Agamma
  - AMPKalpha
  - CrebB
  - CrebA
  - par
  - para
  - par-6
  - ATPsynbeta
  - Atpalpha
  - Desat2
  - Fadd
  - Fad2
  - Desat1
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - amon
  - Idh
  - tgo
  - sima
  - rb
  - ebi
  - E2f2
  - E2f1
  - ewg
  - srl
  - pgc
  - PolG1
  - pyd
  - Low
---
